The safety of the anti-VEGF drugs is not yet completely established in infants though there has been widespread use of anti-VEGF injections since the 2010s, which has influenced treatment patterns of ROP worldwide21,22. This evidence concerns the gene VEGFA and retinopathy of prematurity.